Increased Thromboxane Biosynthesis in Essential Thrombocythemia

Bianca Rocca; Giovanni Ciabattoni; Raffaele Tartaglione; Sergio Cortelazzo; Tiziano Barbui; Carlo Patrono; Raffaele Landolfi

doi:10.1055/s-0038-1649916

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1995; 74(05): 1225-1230
DOI: 10.1055/s-0038-1649916

Original Article

Clinical Studies

Schattauer GmbH Stuttgart

Increased Thromboxane Biosynthesis in Essential Thrombocythemia

Bianca Rocca

¹The Department of Medicine, Catholic University School of Medicine, Rome, Italy

,

Giovanni Ciabattoni

²The Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

,

Raffaele Tartaglione

¹The Department of Medicine, Catholic University School of Medicine, Rome, Italy

,

Sergio Cortelazzo

³The Division of Hematology, Bergamo’;s Civil Hospital, Bergamo, Italy

,

Tiziano Barbui

³The Division of Hematology, Bergamo’;s Civil Hospital, Bergamo, Italy

,

Carlo Patrono

⁴The Department of Pharmacology, University of Chieti “G. D’Annunzio” School of Medicine, Chieti, Italy

,

Raffaele Landolfi

¹The Department of Medicine, Catholic University School of Medicine, Rome, Italy

› Institutsangaben

Abstract

als PDF herunterladen

Summary

In order to investigate the in vivo thromboxane (TX) biosynthesis in essential thromboeythemia (ET), we measured the urinary exeretion of the major enzymatic metabolites of TXB₂, 11-dehydro-TXB₂ and 2,3-dinor-TXB₂ in 40 ET patients as well as in 26 gender- and age-matched controls. Urinary 11-dehydro-TXB₂ was significantly higher (p <0.001) in thrombocythemic patients (4,063 ± 3,408 pg/mg creatinine; mean ± SD) than in controls (504 ± 267 pg/mg creatinine), with 34 patients (85%) having 11-dehydro-TXB₂ >2 SD above the control mean. Patients with platelet number <1,000 × 10₉/1 (n = 25) had significantly higher (p <0.05) 11 -dehydro-TXB2 excretion than patients with higher platelet count (4,765 ± 3,870 pg/mg creatinine, n = 25, versus 2,279 ± 1,874 pg/mg creatinine, n = 15). Average excretion values of patients aging >55 was significantly higher than in the younger group (4,784 ± 3,948 pg/mg creatinine, n = 24, versus 2,405 ± 1,885 pg/mg creatinine, n = 16, p <0.05). Low-dose aspirin (50 mg/d for 7 days) largely suppressed 11-dehydro-TXB₂ excretion in 7 thrombocythemic patients, thus suggesting that platelets were the main source of enhanced TXA₂ biosynthesis. The platelet count-corrected 11-dehydro-TXB₂ excretion was positively correlated with age (r = 0.325, n = 40, p <0.05) and inversely correlated with platelet count (r = -0.381, n = 40, p <0.05). In addition 11 out of 13 (85%) patients having increased count-corrected 11-dehydro-TXB₂ excretion, belonged to the subgroup with age >55 and platelet count <1,000 × 109₉/1. We conclude that in essential thrombocythemia: 1) enhanced 11-dehydro-TXB₂ excretion largely reflects platelet activation in vivo;2) age as well as platelet count appear to influence the determinants of platelet activation in this setting, and can help in assessing the thrombotic risk and therapeutic strategy in individual patients.

PDF (1999 kb)

Referenzen

References
1 Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12
2 Mitus J, Schafer AI. Thrombocytosis and thrombocythemia. Hematol/Oncol Clin North Am 1990; 4: 157-178
3 Schafer AI. Essential thrombocythemia. Progr Haemost Thromb 1991; 10: 69-96
4 Landolfi R, Ciabattoni G, Patrignani P, Castellana M, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965-1971
5 van Genderen P, Michiels J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Press Med 1994; 23: 73-77
6 Fenaux P, Simon M, Cauliere MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556
7 Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R. Essential thrombocythemias. Clinical evolutionary and biological data Cancer 1986; 58: 2240-2247
8 Randi M, Stocco F, Rossi C, Tison T, Girolami A. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients. J Med 1991; 22: 213-223
9 Kessler C, Klein H, Havlik R. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 1982; 50: 157-167
10 Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients Ann Hematol 1991; 63: 101-106
11 Tura S. Le trombocitémie. Haematologica 1979; 64: 179-218
12 Cortelazzo S, Viero P, Finazzi G, D’ Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocytemia. J Clin Oncol 1990; 8: 556-599
13 Hehlmann R, Jahn M, Baumann B, Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases Cancer 1988; 61: 2487-2496
14 Lahuierta-Palaeios J, Bomslein R, Fernandcz-Debora F, Guliémiz-Rivas E, Orliz M, Larregla S, Calandre L, Monlcro-Caslillo J. Controlled and uncontrolled thrombocytosis. Its clinical role inessential thrombocythemia Cancer 1988; 61: 1207-1212
15 Colombi M, Radaelli F, Zocehi L, Maiolo A. Thrombotic and hemorrhagic complications in essential thrombocythemia. Cancer 1991; 67: 2926-2930
16 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castmeei G, De Salvo A, Satta MA, Peskar BA. Low-dose aspirin and inhibition of thromboxane B, production in healthy subjects. Thromb Res 1980; 17: 317-327
17 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. min Invest 1982; 69: 1366-1372
18 Roberts IJ, Sweetman BI, Oates JA. Metabolism of thromboxane B, in man. Identification of twenty urinary metabolites J Biol Chcm 1981; 256: 8384-8393
19 Ciabattoni G, Pugliese F, Davì G, Picrucci A, Simonctti BM, Patrono C. Fractional conversion of thromboxane B, to urinary 11-dehydro thromboxane B₂in man. Biochim Biophys Aeta 1989; 992: 66-70
20 Ciabattoni Cl, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radio immunoassay of I l-dehydro-thromboxanc B₂in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-297
21 Patrono C, Ciabattoni G, Rcmuzzi G, Gotti E, Bombardieri S, Di Munno O, Tartarelli GA, Simonctti BM, Picrucci A. Functional significance of renal prostacyclin and thromboxane A₂production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-1018
22 Alessandrini P, Avogaro P, Bittolo Bon G, Patrignani P, Patrono C. Physiologic variables affecting thromboxane B₂production in human whole blood. Thromb Res 1985; 37: 1-8
23 FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177
24 Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989
25 Vejar M, Fragasso G, Hackett D, Lipkin D, Maseri A, Bom GV R, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas 1990; 6: 163-168
26 Koudstaal P, Ciabattoni G, van Gijn J, Nieuwenhuis HK, de Groot P, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 1993; 24: 219-223
27 Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C, Mancini M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. J Clin Invest 1993; 92: 1400-1406
28 Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774
29 Davì G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992; 85: 1792-1798
30 Burch J, Stanford N, Majerus P. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-9
31 Reilly I, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186
32 Han ZC, Bellucci S, Bodevin E, Shen ZX, Caen JP. In vivo inhibition of megakaryocyte and platelet production by platelet factor 4 in mice. C R Acad Sci 1991; 313: 553-558
33 Preston FE, Emmanuel IG, Winfield DA, Malia RG. Essential thrombocythaemia and peripheral gangrene. BMJ 1974; 3: 548-552
34 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989; 320: 915-924
35 Iuliano L, Pedersen JZ, Praticò D, Rotilio G, Violi F. Role of hydroxyl radicals in the activation of human platelets. Eur J Biochem 1994; 221: 695-704
36 Mcintyre K, Hoagland H, Silverstein M, Petit R, Hoagland HC, Silverstein MN, Petitt RM. Essential thrombocythemia in young adults. Mayo Clin Proc 1991; 66: 149-154
37 Randi ML, Fabris F, Rossi C, Tison T, Barbone E, Girolami A. Sex and age as prognostic factors in essential thrombocythemia. Haematologica 1992; 77: 402-404
38 Randi ML, Fabris F, Girolami A. Thrombocytosis in young people:evaluation of 57 cases diagnosed before the age of 40. Blut 1990; 60: 233-237
39 Mitus AJ, Barbui T, Shulman N, Rosenthal D, Viero P, Cortelazzo S, Schafer AI. Hemostatic complications in young patients with essential thrombocythemia. Am J Med 1990; 88: 371-375
40 Millard FE, Hunter CS, Anderson M, Edelman MJ, Kosty MP, Luiken GA, Marino GG. Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 1990; 33: 27-31
41 Barbui T, Buelli M, Cortelazzo S, Viero P. Aspirin and risk of bleeding in patients with thrombocythemia. Am J Med 1987; 83: 265-266
42 Vreeken J, van Aken WG. Spontaneous aggregation of blood platelets as a cause of idiopathic and recurrent painful toes and fingers. Lancet 1971; 2: 1394-1397
43 Michiels JJ, ten Cate FW J, Vuzevski VD, Abels J. Histopathology of erythromelalgia in thrombocythaemia. Histopathology 1984; 8: 669-678
44 Michiels J, Abels J, Steketee J, van Vliet HH D M, Vuzevski KD. Erythromelalgia caused by platelet-mediated arteriolarinflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102: 466-471
45 Michiels JJ, van Joost TH. Erythromelalgia and thrombocythemia. A causal relation J Amer Acad Dermatol 1990; 22: 101-111
46 Michiels J, Zijlstra F. Prostaglandin cyclooxygenase products but not thromboxane A₂are involved in the pathogenesis of erythromelalgia in thrombocythaemia. Mediators of Inflammation 1993; 2: 385-389
47 Drenth JP H, Michiels JJ. Erythromelalgia and erythermalgia: diagnostic differentiation. Int J Dermatol 1994; 33: 393-397
48 Michiels JJ, Koudstaal PJ, Mulder AH, vanVliet HH D M. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993; 43: 1101-1110
49 Jabaily J, Hand HJ, Lazio J, Massey EW, Faguet GB, Briere J, Landaw SA, Pisciotta AV. Neurologic manifestations of essential thrombocythemia. Ann Intern Med 1983; 99: 513-518
50 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294